← Leaderboards
Zhen Fan
University Of Tx Md Anderson Can Ctr
$6,110,278
Attributed
$6,110,278
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $594K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,110,278 · 4
By mechanism
R01$5,675,778 · 3
R21$434,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Anil K Sood$29,572,737
- Michael J Galko$9,739,468
- Laszlo George Radvanyi$2,629,361
- John F De Groot$2,436,888
- Candelaria Gomez-Manzano$2,523,797
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingEpidermal Growth Factor ReceptorMalignant NeoplasmsTumorCancer CellOverexpressionProductionCellsReceptorMonoclonal AntibodiesPlaySignal TransductionEngineeringSolid NeoplasmBasePharmaceutical PreparationsResponseCessation Of LifeCytokineTrastuzumabInvestigationBinding (Molecular Function)Malignant Breast NeoplasmNovel Therapeutics
Grant awards (17)
Developing novel bispecific antibodies for cancer treatment$594,007
R01 · FY2025 · CA · contact PI
Developing novel bispecific antibodies for cancer treatment$564,306
R01 · FY2024 · CA · contact PI
Developing novel bispecific antibodies for cancer treatment$294,116
R01 · FY2023 · CA · contact PI
Developing novel bispecific antibodies for cancer treatment$487,412
R01 · FY2022 · CA · contact PI
Developing novel bispecific antibodies for cancer treatment$497,359
R01 · FY2021 · CA · contact PI
A novel targeted therapy for HNSCC based on a novel activity of cetuximab$332,000
R01 · FY2018 · CA · contact PI
A novel targeted therapy for HNSCC based on a novel activity of cetuximab$332,000
R01 · FY2017 · CA · contact PI
A novel targeted therapy for HNSCC based on a novel activity of cetuximab$332,000
R01 · FY2016 · CA · contact PI
A novel targeted therapy for HNSCC based on a novel activity of cetuximab$332,000
R01 · FY2015 · CA · contact PI
A novel targeted therapy for HNSCC based on a novel activity of cetuximab$332,000
R01 · FY2014 · CA · contact PI
Mechanisms of tumor resistance to anti-HER/ErbB therapeutics$309,964
R01 · FY2012 · CA · contact PI
Developing a novel recombinant antibody for treatment of oral cancer$197,500
R21 · FY2012 · DE · contact PI
Mechanisms of tumor resistance to anti-HER/ErbB therapeutics$309,964
R01 · FY2011 · CA · contact PI
Developing a novel recombinant antibody for treatment of oral cancer$237,000
R21 · FY2011 · DE · contact PI
Mechanisms of tumor resistance to anti-HER/ErbB therapeutics$319,550
R01 · FY2010 · CA · contact PI
Mechanisms of tumor resistance to anti-HER/ErbB therapeutics$319,550
R01 · FY2009 · CA · contact PI
Mechanisms of tumor resistance to anti-HER/ErbB therapeutics$319,550
R01 · FY2008 · CA · contact PI